<?xml version="1.0" encoding="utf-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0" xml:base="https://www.fiercepharma.com/">
  <channel>
    <title>Fierce Pharma</title>
    <link>https://www.fiercepharma.com/</link>
    <description>a feed of the latest articles on our website</description>
    <language>en</language>
    
    <item>
  <title><a href="/pharma/fierce-pharma-regulatory-tracker-2026-h2" hreflang="en">Regulatory tracker: Novo's Sogroya wins 4th label expansion this year</a></title>
  <link>https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-2026-h2</link>
  <description>In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.</description>
  <pubDate>Jul 1, 2026 1:33pm</pubDate>
    <dc:creator><a href="/person/angus-liu-0" hreflang="en">Angus Liu</a>, <a href="/person/kevin-dunleavy-0" hreflang="en">Kevin Dunleavy</a>, <a href="/person/fraiser-kansteiner-0" hreflang="en">Fraiser Kansteiner</a>, <a href="/person/donavyn-coffey" hreflang="en">Donavyn Coffey</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/a6f8f591-bb07-4a55-b9ca-16ca7271358a</guid>
    </item>
<item>
  <title><a href="/pharma/merck-scores-us-german-wins-over-halozyme-keytruda-qlex-patent-fight" hreflang="en">Merck scores US, German wins over Halozyme in Keytruda Qlex patent fight</a></title>
  <link>https://www.fiercepharma.com/pharma/merck-scores-us-german-wins-over-halozyme-keytruda-qlex-patent-fight</link>
  <description>Merck &amp;amp; Co. has delivered a one-two legal punch against Halozyme Therapeutics, clearing major commercialization hurdles for subcutaneous Keytruda in the U.S. and Germany.</description>
  <pubDate>Nov 20, 2026 1:50pm</pubDate>
    <dc:creator><a href="/person/angus-liu-0" hreflang="en">Angus Liu</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/cc8a6e18-4cd3-4054-a5f5-5158af614f50</guid>
    </item>
<item>
  <title><a href="/pharma/mapping-psychedelics-commercial-summit" hreflang="en">Mapping psychedelics’ commercial summit</a></title>
  <link>https://www.fiercepharma.com/pharma/mapping-psychedelics-commercial-summit</link>
  <description>Several years after the FDA's high-profile rejection of Lykos Therapeutics’ MDMA candidate for post-traumatic stress disorder, a new wave of developers is nearing the regulatory finish line with experimental psychedelic treatments for mental health conditions. But regulatory approval is, in many ways, just the beginning of a complex journey to market for these companies, should their drugs pass muster with the FDA.</description>
  <pubDate>Nov 20, 2026 1:38pm</pubDate>
    <dc:creator><a href="/person/fraiser-kansteiner-0" hreflang="en">Fraiser Kansteiner</a>, <a href="/person/donavyn-coffey" hreflang="en">Donavyn Coffey</a>, <a href="/person/ayla-ellison" hreflang="en">Ayla Ellison</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/49d4e273-84a6-4d41-945e-026b75dbee20</guid>
    </item>
<item>
  <title><a href="/biotech/mercks-trop2-adc-extends-survival-pivotal-gastroesophageal-cancer-trial" hreflang="en">Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trial</a></title>
  <link>https://www.fiercepharma.com/biotech/mercks-trop2-adc-extends-survival-pivotal-gastroesophageal-cancer-trial</link>
  <description>Merck &amp;amp; Co.’s sacituzumab tirumotecan has improved overall survival in a phase 3 cancer trial, delivering a second pivotal global victory for the TROP2-directed antibody-drug conjugate.</description>
  <pubDate>Nov 20, 2026 7:53am</pubDate>
    <dc:creator><a href="/person/nick-paul-taylor" hreflang="en">Nick Paul Taylor</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/8de08e68-21d3-472b-bc9c-8b138e109d43</guid>
    </item>
<item>
  <title><a href="/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill" hreflang="en">The Oral GLP-1 Tracker: Foundayo holds steady as Wegovy pill takes a 5% dip</a></title>
  <link>https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill</link>
  <description>Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions.</description>
  <pubDate>Apr 21, 2026 10:06am</pubDate>
    <dc:creator><a href="/person/angus-liu-0" hreflang="en">Angus Liu</a>, <a href="/person/kevin-dunleavy-0" hreflang="en">Kevin Dunleavy</a>, <a href="/person/fraiser-kansteiner-0" hreflang="en">Fraiser Kansteiner</a>, <a href="/person/donavyn-coffey" hreflang="en">Donavyn Coffey</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/95fc1f29-4c60-4c4e-85a1-7e3739ee4672</guid>
    </item>
<item>
  <title><a href="/pharma/another-215-layoffs-linked-novos-new-jersey-hq" hreflang="en">Another 215 layoffs linked to Novo's New Jersey HQ</a></title>
  <link>https://www.fiercepharma.com/pharma/another-215-layoffs-linked-novos-new-jersey-hq</link>
  <description>Novo will trim 215 jobs reporting to its New Jersey headquarters starting in February as part of a "redesign" of its U.S. sales organization.  </description>
  <pubDate>Nov 20, 2026 10:08am</pubDate>
    <dc:creator><a href="/person/donavyn-coffey" hreflang="en">Donavyn Coffey</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/410c0f64-35d5-470a-9dfd-8d42a50a5219</guid>
    </item>
<item>
  <title><a href="/pharma/fda-sets-new-safety-council-under-cber-keep-tabs-approved-vaccines-cell-and-gene-therapies" hreflang="en">FDA sets up new safety council to keep tabs on approved vaccines, cell and gene therapies</a></title>
  <link>https://www.fiercepharma.com/pharma/fda-sets-new-safety-council-under-cber-keep-tabs-approved-vaccines-cell-and-gene-therapies</link>
  <description>The FDA's Center for Biologics Evaluation and Research is setting up a new governance body focused on safety oversight of products like cell and gene therapies and vaccines once they’ve hit the market.</description>
  <pubDate>Nov 20, 2026 10:48am</pubDate>
    <dc:creator><a href="/person/fraiser-kansteiner-0" hreflang="en">Fraiser Kansteiner</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/ec6237a3-6792-4427-ba79-1b11c83be008</guid>
    </item>
<item>
  <title><a href="/pharma/ivonescimab-fda-rejection-pfizer-vivo-car-t-deal-china-fires-scientists-fatal-gene-trial" hreflang="en">Fierce Pharma Asia—Ivonescimab’s FDA snub; Pfizer’s in vivo CAR-T deal; China fires scientists in fatal gene trial</a></title>
  <link>https://www.fiercepharma.com/pharma/ivonescimab-fda-rejection-pfizer-vivo-car-t-deal-china-fires-scientists-fatal-gene-trial</link>
  <description>The FDA's complete response letter for Summit and Akeso's ivonescimab reveals more grievances than just an overall survival miss. Pfizer is licensing three in vivo autoimmune CAR-T programs from China's Starna Therapeutics. Chinese authorities have handed out penalties to individuals and organizations involved in a gene editing trial that led to a child's death. And more.</description>
  <pubDate>Nov 20, 2026 9:46am</pubDate>
    <dc:creator><a href="/person/angus-liu-0" hreflang="en">Angus Liu</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/c66be110-46e8-4873-8bd3-def280d385ff</guid>
    </item>
<item>
  <title><a href="/pharma/sanofi-snags-fda-nod-become-first-neurologic-treatment-rare-gd3" hreflang="en">Sanofi gets Genzyme asset across FDA finish line with key nod in Gaucher type 3</a></title>
  <link>https://www.fiercepharma.com/pharma/sanofi-snags-fda-nod-become-first-neurologic-treatment-rare-gd3</link>
  <description>Sanofi's Infilbray secured an FDA approval to treat children and adults with the rare metabolic and neurogenerative disorder Type 3 Gaucher disease. The daily oral therapy is the first to address the disease's neurological effects. </description>
  <pubDate>Nov 19, 2026 4:17pm</pubDate>
    <dc:creator><a href="/person/donavyn-coffey" hreflang="en">Donavyn Coffey</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/7f32557d-eb9f-4e77-a063-9aac118a167f</guid>
    </item>
<item>
  <title><a href="/marketing/biogen-unblurs-life-friedreich-ataxia-patient-centered-skyclarys-campaign" hreflang="en">Biogen unblurs life with Friedreich ataxia in patient-centered Skyclarys campaign</a></title>
  <link>https://www.fiercepharma.com/marketing/biogen-unblurs-life-friedreich-ataxia-patient-centered-skyclarys-campaign</link>
  <description>The company’s visual-forward campaign depicts real Friedreich ataxia patients enjoying some favorite activities while fast-moving life blurs around them, reminding prospective Skyclarys users that while “life moves fast, progression doesn’t have to.” </description>
  <pubDate>Nov 19, 2026 1:24pm</pubDate>
    <dc:creator><a href="/person/zoey-becker" hreflang="en">Zoey Becker</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/354f9ec0-5150-4663-979b-023586011df4</guid>
    </item>
<item>
  <title><a href="/pharma/facing-down-dupixent-cliff-sanofi-mulls-buyout-insmed-and-its-blockbuster-be-brinsupri" hreflang="en">Facing down Dupixent cliff, Sanofi mulls buyout of Insmed and its blockbuster-to-be Brinsupri: Bloomberg</a></title>
  <link>https://www.fiercepharma.com/pharma/facing-down-dupixent-cliff-sanofi-mulls-buyout-insmed-and-its-blockbuster-be-brinsupri</link>
  <description>After Sanofi leadership telegraphed an upsized appetite for business development last month, signals have emerged that the French Pharma may be eyeing a deal to acquire Insmed, the developer of new respiratory medicine Brinsupri, which appears well on its way to cementing its blockbuster status this year.&amp;nbsp; </description>
  <pubDate>Nov 19, 2026 1:10pm</pubDate>
    <dc:creator><a href="/person/fraiser-kansteiner-0" hreflang="en">Fraiser Kansteiner</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/98f94f26-c919-45e6-a2fc-8fc262c9ea30</guid>
    </item>
<item>
  <title><a href="/pharma/novartis-staring-down-167b-post-2030-patent-cliff-cuts-mid-term-growth-forecast" hreflang="en">Novartis CEO, staring down $16.7B post-2030 patent cliff, challenges Wall Street consensus</a></title>
  <link>https://www.fiercepharma.com/pharma/novartis-staring-down-167b-post-2030-patent-cliff-cuts-mid-term-growth-forecast</link>
  <description>Novartis is gearing up to defend its growth trajectory against a steep wave of patent expirations in the early 2030s, as the upcoming U.S. generic entry for breast cancer blockbuster Kisqali prompted the Swiss drugmaker to trim its mid-term revenue outlook.</description>
  <pubDate>Nov 19, 2026 11:02am</pubDate>
    <dc:creator><a href="/person/angus-liu-0" hreflang="en">Angus Liu</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/f8ba88eb-7b0d-4953-965d-6177f68e9bf7</guid>
    </item>
<item>
  <title><a href="/pharma/arcera-ponies-1b-innogens-china-approved-glp-1" hreflang="en">Arcera strikes $1B+ pact to license Innogen's approved GLP-1 outside China</a></title>
  <link>https://www.fiercepharma.com/pharma/arcera-ponies-1b-innogens-china-approved-glp-1</link>
  <description>Arcera Life Sciences has agreed to potentially pay more than $1 billion to license Innogen's China-approved GLP-1 in places like Africa, Latin America and the Middle East. </description>
  <pubDate>Nov 19, 2026 10:45am</pubDate>
    <dc:creator><a href="/person/donavyn-coffey" hreflang="en">Donavyn Coffey</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/a4e499c4-7d8f-46db-aa49-036d738767ea</guid>
    </item>
<item>
  <title><a href="/pharma/regeneron-breaks-through-neurology-barrier-fda-nod-crowded-myasthenia-gravis" hreflang="en">Regeneron breaks into neurology with FDA nod in crowded myasthenia gravis</a></title>
  <link>https://www.fiercepharma.com/pharma/regeneron-breaks-through-neurology-barrier-fda-nod-crowded-myasthenia-gravis</link>
  <description>Underscoring how crowded the U.S. market for generalized myasthenia gravis (gMG) has become, the FDA on Wednesday approved the second targeted therapy for the neuromuscular disease this week, with the latest honor going to Regeneron and its Alnylam-licensed siRNA drug cemdisiran. </description>
  <pubDate>Nov 19, 2026 10:29am</pubDate>
    <dc:creator><a href="/person/fraiser-kansteiner-0" hreflang="en">Fraiser Kansteiner</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/e697b5ae-670d-4480-a12c-685e41c8737f</guid>
    </item>
<item>
  <title><a href="/marketing/jj-draws-fda-rebuke-misstating-inlexzos-bladder-sparing-benefits" hreflang="en">J&amp;J draws FDA rebuke for misstating Inlexzo’s bladder-sparing benefits</a></title>
  <link>https://www.fiercepharma.com/marketing/jj-draws-fda-rebuke-misstating-inlexzos-bladder-sparing-benefits</link>
  <description>The FDA has slammed Johnson &amp;amp; Johnson over misleading claims about its bladder cancer drug Inlexzo, accusing the pharma company of basing statements on uninterpretable data.</description>
  <pubDate>Nov 19, 2026 10:46am</pubDate>
    <dc:creator><a href="/person/nick-paul-taylor" hreflang="en">Nick Paul Taylor</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/d3d69ae5-82df-4fba-a5f1-317c32ba43e3</guid>
    </item>
<item>
  <title><a href="/manufacturing/lotte-inks-production-deal-cdmo-preps-open-33b-south-korean-plant" hreflang="en">CDMO Lotte inks commercial production deal as work on South Korean plant wraps</a></title>
  <link>https://www.fiercepharma.com/manufacturing/lotte-inks-production-deal-cdmo-preps-open-33b-south-korean-plant</link>
  <description>Lotte Biologics, which was established in 2022, inked a major manufacturing deal with an unnamed pharmaceutical company as the South Korean CDMO gears up for commercial production at its new multi-billion-dollar Songdo Bio Campus near Seoul.&lt;br&gt;
</description>
  <pubDate>Nov 19, 2026 8:27am</pubDate>
    <dc:creator><a href="/person/joseph-keenan" hreflang="en">Joseph Keenan</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/92274b94-1530-4b49-8520-ae681853748b</guid>
    </item>
<item>
  <title><a href="/sponsored/ais-real-prize-building-tomorrows-ci-capability" hreflang="en">AI’s Real Prize: Building Tomorrow’s CI Capability</a></title>
  <link>https://www.fiercepharma.com/sponsored/ais-real-prize-building-tomorrows-ci-capability</link>
  <description>AI is becoming a commodity. Javier Vega explains why the next advantage in competitive intelligence comes from people, judgment and scale.</description>
  <pubDate>Nov 12, 2026 11:23am</pubDate>
    <dc:creator><a href="/person/questex-partner" hreflang="en">Questex Partner</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/d0f7df8e-9f16-4038-becc-854ffaf9cef0</guid>
    </item>
<item>
  <title><a href="/biotech/novartis-ceo-argues-shareholders-happy-overall-calls-coins-act-adjustment" hreflang="en">Novartis CEO argues shareholders ‘happy overall’ with strategy, calls for COINS Act adjustment</a></title>
  <link>https://www.fiercepharma.com/biotech/novartis-ceo-argues-shareholders-happy-overall-calls-coins-act-adjustment</link>
  <description>Despite a bumpy few months for Novartis that saw a couple of high-profile clinical setbacks, CEO Vas Narasimhan has told Fierce he believes most shareholders remain onside with the company’s strategy.</description>
  <pubDate>Nov 19, 2026 4:20am</pubDate>
    <dc:creator><a href="/person/james-waldron" hreflang="en">James Waldron</a>, <a href="/person/angus-liu-0" hreflang="en">Angus Liu</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/97920112-375d-45b1-b0d5-f5626d7888d2</guid>
    </item>
<item>
  <title><a href="/pharma/bms-ph-3-alzheimers-agitation-teaser-builds-confidence-cobenfy-expansion-plan" hreflang="en">BMS' ph. 3 Alzheimer's psychosis teaser builds confidence in Cobenfy expansion plan</a></title>
  <link>https://www.fiercepharma.com/pharma/bms-ph-3-alzheimers-agitation-teaser-builds-confidence-cobenfy-expansion-plan</link>
  <description>After delaying the phase 3 readout of its Alzheimer’s psychosis program for Cobenfy earlier this year, Bristol Myers Squibb is offering an early peek that appears to bode well for the high-stakes data drops ahead, even as the fine details remain hazy. </description>
  <pubDate>Nov 18, 2026 3:54pm</pubDate>
    <dc:creator><a href="/person/fraiser-kansteiner-0" hreflang="en">Fraiser Kansteiner</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/d70220eb-d54b-4c39-bef8-aa48bdc60dad</guid>
    </item>
<item>
  <title><a href="/pharma/beren-clinches-long-awaited-fda-nod-niemann-pick-disease" hreflang="en">Beren clinches long-awaited FDA nod for cyclodextrin drug in Niemann-Pick disease</a></title>
  <link>https://www.fiercepharma.com/pharma/beren-clinches-long-awaited-fda-nod-niemann-pick-disease</link>
  <description>Beren Therapeutic's Lembaz was cleared by the FDA to treat the neurogenerative disorder Niemann-Pick disease type C in children as small as 15 pounds. It's the first NPC treatment to improve survival and to treat the cholesterol transport dysfunction that drives the disease. </description>
  <pubDate>Nov 18, 2026 11:27am</pubDate>
    <dc:creator><a href="/person/donavyn-coffey" hreflang="en">Donavyn Coffey</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/a3f20aa1-3955-454c-9cf5-0f24b3dd9f79</guid>
    </item>
<item>
  <title><a href="/pharma/fda-moves-yank-salernos-liquid-cholesterol-med-approval-missing-reports" hreflang="en">FDA moves to yank Salerno's liquid cholesterol drug approval on missing reports</a></title>
  <link>https://www.fiercepharma.com/pharma/fda-moves-yank-salernos-liquid-cholesterol-med-approval-missing-reports</link>
  <description>In a notice posted on the Federal Register Wednesday, the FDA said that it has proposed withdrawing the approval for Salerno’s FloLipid, an oral suspension formulation of the long-approved cholesterol lowering medication simvastatin. </description>
  <pubDate>Nov 18, 2026 9:45am</pubDate>
    <dc:creator><a href="/person/fraiser-kansteiner-0" hreflang="en">Fraiser Kansteiner</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/83dcc1f1-1ff8-4ba7-89aa-cdfb3416eb8e</guid>
    </item>
<item>
  <title><a href="/marketing/novo-expands-dtc-program-novocare-support-wegovy-users-through-holistic-health-journey" hreflang="en">Novo expands DTC program Novocare to support Wegovy users through holistic health journey</a></title>
  <link>https://www.fiercepharma.com/marketing/novo-expands-dtc-program-novocare-support-wegovy-users-through-holistic-health-journey</link>
  <description>Members who sign up for Novo's new Novocare can benefit from holistic health services meant to support Wegovy users throughout the entirety of their weight loss journey. &lt;br&gt;
</description>
  <pubDate>Nov 17, 2026 2:47pm</pubDate>
    <dc:creator><a href="/person/zoey-becker" hreflang="en">Zoey Becker</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/ef69a880-2763-419e-a80d-e53d5b2c1bbb</guid>
    </item>
<item>
  <title><a href="/pharma/overtons-fda-nomination-has-been-pulled-white-house" hreflang="en">Heidi Overton’s FDA nomination pulled by White House</a></title>
  <link>https://www.fiercepharma.com/pharma/overtons-fda-nomination-has-been-pulled-white-house</link>
  <description>The White House is pulling Heidi Overton’s nomination to lead the FDA just hours before the Senate was scheduled to vote on her confirmation.</description>
  <pubDate>Nov 17, 2026 8:44pm</pubDate>
    <dc:creator><a href="/person/marissa-russo" hreflang="en">Marissa Russo</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/48ea86d1-1a1f-4ebd-a394-f502546e026d</guid>
    </item>
<item>
  <title><a href="/pharma/fdas-complete-response-letter-summit-ivonescimab-cites-china-heavy-data-beyond-survival-miss" hreflang="en">FDA’s complete response letter for Summit’s ivonescimab cites China-heavy data beyond survival miss</a></title>
  <link>https://www.fiercepharma.com/pharma/fdas-complete-response-letter-summit-ivonescimab-cites-china-heavy-data-beyond-survival-miss</link>
  <description>The FDA’s rejection of Summit Therapeutics’ closely watched PD-1xVEGF bispecific ivonescimab extends beyond its previously reported failure to show a statistically significant overall survival benefit.</description>
  <pubDate>Nov 17, 2026 4:29pm</pubDate>
    <dc:creator><a href="/person/angus-liu-0" hreflang="en">Angus Liu</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/43a3a527-0147-4393-b3f3-a2ac0e18a899</guid>
    </item>
<item>
  <title><a href="/pharma/cosentyx-bags-fda-nod-11th-indication-novartis-looks-2029-patent-cliff" hreflang="en">Cosentyx bags FDA nod for 11th indication as Novartis looks to buffer 2029 patent cliff</a></title>
  <link>https://www.fiercepharma.com/pharma/cosentyx-bags-fda-nod-11th-indication-novartis-looks-2029-patent-cliff</link>
  <description>Cosentyx's latest FDA approval marks the aging biologic's 11th indication and the first of the anti-IL-17 class to be approved for polymyalgia rheumatica.</description>
  <pubDate>Nov 17, 2026 11:33am</pubDate>
    <dc:creator><a href="/person/donavyn-coffey" hreflang="en">Donavyn Coffey</a></dc:creator>
    <guid isPermaLink="true">https://www.fiercepharma.com/cf211b85-6eec-47f1-bb13-e5ccb75aa076</guid>
    </item>

  </channel>
</rss>
